Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding

Antivir Ther. 2011;16(5):621-8. doi: 10.3851/IMP1813.

Abstract

It is estimated there are 350-400 million people worldwide chronically infected with HBV. Many of these are women and of reproductive age. As such, they may face therapeutic decisions regarding antiviral therapy and the implication this may have on future or current pregnancies. This article reviews the data of all antivirals licensed for use against hepatitis B infection regarding teratogenicity, carcinogenicity, clinical experience during pregnancy, placental transfer and excretion in breast milk.

Publication types

  • Review

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Breast Feeding*
  • Female
  • Guanine / analogs & derivatives
  • Guanine / therapeutic use
  • Hepatitis B / drug therapy*
  • Hepatitis B virus / drug effects
  • Hepatitis B, Chronic / drug therapy
  • Humans
  • Interferon-alpha / therapeutic use
  • Lamivudine / therapeutic use
  • Nucleosides / therapeutic use
  • Organophosphonates / therapeutic use
  • Placenta / drug effects
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pyrimidinones / therapeutic use
  • Telbivudine
  • Tenofovir
  • Thymidine / analogs & derivatives

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Nucleosides
  • Organophosphonates
  • Pyrimidinones
  • Telbivudine
  • Lamivudine
  • entecavir
  • Guanine
  • Tenofovir
  • Adenine
  • adefovir dipivoxil
  • Thymidine